GLP-3, GLP-1, and GLP-2 Explained: A Researcher’s Guide to the Peptide Family

The term "GLP-3" now appears in clinical trial press releases, investor calls, and research databases — yet no such peptide exists in standard biochemistry textbooks. That naming gap reveals something important: the glucagon-like peptide family is evolving faster than its own vocabulary. This guide to GLP-3, GLP-1, and GLP-2 explained as a peptide family cuts through the marketing language to focus on mechanism, receptor biology, and what the evidence actually shows.

Key Takeaways

• GLP-1 and GLP-2 are both derived from the same precursor protein, proglucagon, through tissue-specific processing.
• GLP-1 targets the GLP-1 receptor to regulate insulin secretion and appetite; GLP-2 targets a separate receptor to support intestinal growth and repair.
• "GLP-3" is an informal nickname for retatrutide, a triple agonist hitting GLP-1, GIP, and glucagon receptors — not a distinct endogenous peptide.
• Multiple next-generation agents in 2026 are blurring receptor boundaries, making precise terminology more important than ever.
• Researchers should distinguish receptor pharmacology from peptide taxonomy to avoid conflating mechanism with marketing.

The Proglucagon Origin: Where GLP-1 and GLP-2 Begin

Understanding GLP-3, GLP-1, and GLP-2 explained as a peptide family starts with a single precursor: proglucagon. This 160-amino-acid protein is encoded by the GCG gene and processed differently depending on the tissue.

Tissue-specific cleavage produces distinct peptides:

This differential processing is controlled by prohormone convertases — PC2 in the pancreas and PC1/3 in the gut and brain. The result is that GLP-1 and GLP-2 are co-secreted from intestinal L-cells in a roughly 1:1 molar ratio following nutrient ingestion.

GLP-1 (glucagon-like peptide-1) is a 30-amino-acid incretin hormone. It binds the GLP-1 receptor (GLP-1R), a class B G-protein-coupled receptor expressed in pancreatic beta cells, the vagus nerve, the hypothalamus, and the heart. Activation drives glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying, and reduces appetite. Its plasma half-life is under two minutes due to rapid degradation by DPP-4 enzyme.

GLP-2 (glucagon-like peptide-2) is a 33-amino-acid peptide that binds its own distinct receptor, GLP-2R, expressed primarily in intestinal enteroendocrine cells, submucosal neurons, and the hypothalamus. Its core functions center on intestinal epithelial growth, barrier integrity, and nutrient absorption — not glucose regulation. Teduglutide (Gattex/Revestive), a GLP-2 analog, is the only approved agent in this class and generates over $800 million annually. As of 2026, at least six novel GLP-2 analog programs are in active clinical development targeting short bowel syndrome, Crohn's disease, and gut barrier dysfunction. Researchers exploring GLP-1 incretin research themes will find the GLP-2 pathway a compelling parallel.

"GLP-1 and GLP-2 are not interchangeable — they share a precursor but act on entirely different receptor systems with non-overlapping physiological roles."

What "GLP-3" Actually Means: Receptor Taxonomy vs. Peptide Naming

The phrase "GLP-3" does not describe a third endogenous glucagon-like peptide. It is an informal shorthand for retatrutide, a synthetic triple agonist developed by Eli Lilly that simultaneously targets three receptors: GLP-1R, GIP receptor (GIPR), and glucagon receptor (GCGR). The "3" refers to the number of receptor targets, not a peptide sequence.

This distinction matters enormously for researchers. Calling retatrutide "GLP-3" is pharmacologically imprecise. The correct terminology is triple receptor agonist or GLP-1/GIP/glucagon tri-agonist. Retatrutide is not FDA-approved as of 2026 and remains available only through clinical trials. Phase 3 data have shown up to 28.7% weight loss, with approval anticipated no earlier than 2027. For more on this compound's research profile, see the dedicated retatrutide and GLP-3 research overview.

Why does the naming confusion persist?

• Dual agonists like tirzepatide (GLP-1/GIP) were informally called "GLP-2" by some media outlets before that term was corrected.
• The pharmaceutical pipeline moves faster than regulatory taxonomy.
• Marketing teams favor simple numerical progressions.

Researchers should also note the generational differences across GLP-1 drug classes to contextualize where triple agonists sit in the therapeutic timeline.

The 2026 Pipeline: Next-Generation Agents Across the GLP Family

The peptide family landscape in 2026 is defined by receptor combination strategies rather than single-target approaches. Key agents include:

Orforglipron (Foundayo) — Eli Lilly
A once-daily oral GLP-1 receptor agonist. In the ACHIEVE-3 trial, the 17.2 mg dose produced 57.1% greater relative A1C reduction and 73.6% greater relative weight loss compared to oral semaglutide 14 mg. Lilly plans FDA submission by end of Q2 2026.

PF-08653944 — Pfizer
An ultra-long-acting injectable GLP-1 RA achieving 12.3% mean placebo-adjusted weight loss at 28 weeks in the VESPER-3 Phase 2b study, with weight loss continuing after transitioning from weekly to monthly dosing. Ten Phase 3 trials are anticipated in 2026.

Amycretin — Novo Nordisk
A single molecule activating both amylin and GLP-1 receptors, showing 22% weight loss in 36 weeks in Phase 1b/2a trials. Both oral and injectable formulations advance to Phase 3 in 2026.

Survodutide — Boehringer Ingelheim
A dual glucagon/GLP-1 agonist showing 18.7% weight loss at 46 weeks in Phase 2, with 62% of MASH patients achieving disease resolution. Phase 3 trials span 14 countries.

Researchers interested in the broader metabolic peptide landscape can explore metabolic modulation research lines and GIP receptor biology for mechanistic context. Those studying adjacent metabolic compounds may also find value in reviewing AOD9604 metabolic research and SLU-PP-332 metabolic research as comparative reference points.

Conclusion

The GLP peptide family is one of the most productive areas in current biomedical research, but imprecise language creates real confusion. GLP-1 and GLP-2 are endogenous peptides with distinct receptors and non-overlapping functions — both derived from proglucagon but acting on entirely separate physiological systems. "GLP-3" is not a peptide; it is a colloquial label for a triple-receptor agonist strategy.

Actionable next steps for researchers:

• Anchor all literature searches to receptor nomenclature (GLP-1R, GLP-2R, GIPR, GCGR) rather than informal drug nicknames.
• Track the orforglipron and retatrutide Phase 3 readouts expected in 2026-2027 as benchmark data for receptor combination strategies.
• Distinguish between endogenous peptide biology and synthetic analog pharmacology when designing assay protocols.
• Review the GLP-1 peptide product research library for current research-grade compound availability.

Precise taxonomy is not pedantry — it is the foundation of reproducible science.